We investigate the relationship between brain extracellular fluid free phenytoin concentration and plasma free phenytoin concentration in adults with acute brain injury. Daily cerebral microdialysate free phenytoin concentration was measured in eight adults with acute brain injury and compared to simultaneous measurement of plasma free phenytoin concentration.
Introduction
Seizures are a well recognised complication of acute brain injury (ABI), and have been described in the context of both traumatic brain injury (TBI) and subarachnoid haemorrhage (SAH) [1] [2] [3] [4] [5] . Patients with TBI often suffer from seizures during neurocritical care and these seizures can occur despite the administration of phenytoin 6 . The 5 year cumulative incidence of seizures after severe TBI has been estimated as 10% with the highest risk period being in the first year after injury when the standardised incidence ratio is 95.0 7 . After SAH the incidence of in-hospital seizures has been reported as 7% 8 . Seizures in the acute phase after acute brain injury have potentially deleterious effects due to exacerbation of secondary brain injury and seizure management is therefore an important component of neurocritical care.
Phenytoin is a first line treatment for seizures post ABI but potential toxicity requires that drug level monitoring forms an integral part of dosing strategy. It is a drug with a high degree of protein binding and dosing is therefore traditionally based on the plasma concentration of free non-protein bound phenytoin ([Phen PLASMA ]). However, the sites of action of phenytoin as an antiepileptic drug are at the neuronal sodium and calcium channels 9 and drug concentrations at these sites may be poorly reflected by plasma unbound drug concentration. recovery study, and in the microdialysate, using the assay described below.
Materials and Methods

In Vitro Recovery Study
Relative recovery for each catheter was calculated by expressing the microdialysate phenytoin concentrations as a percentage of the mean of the pre and post study phenytoin concentrations in the solutions. All subjects were treated with an initial intravenous loading dose of 15 mg/kg of phenytoin sodium (molecular weight 274.3 Da), followed by a daily oral phenytoin sodium dose of 300 mg, or equivalent dose of phenytoin liquid (molecular weight 252.3 Da), administered at 2200 hours, and commencing the day after the initial loading dose. In all subjects, the initial loading dose of phenytoin was administered at least 24 hours prior to the first blood and microdialysate sample collection. One subject (subject 2) received a second loading dose of 500 mg of phenytoin at 1900 hours on day 3 of blood and microdialysate sampling. None of the patients included in this study were receiving verapamil or probenecid which inhibit P-glycoprotein, and multi-drug resistance associated protein transporters, and might therefore affect neuronal phenytoin uptake 13 .
In Vivo Patient Study
Daily blood and microdialysate samples were taken at 0600 hours each morning. Samples were stored at -80 0 C prior to assay. Plasma (300µl) was pipetted into the sample reservoir of an Amicon Centrifree micropartition system (Millipore, Hertfordshire, U.K.) in accordance with manufacturer's instructions, and centrifuged for 15 min at 3 000 g at a temperature setting of 25 ºC in a Sigma 2K15 refrigerated centrifuge (Sigma, Dorset, U.K.). 
Results
In Vitro Recovery
Relative recovery was 2.1 % for both the catheters studied.
In Vitro Patient Study
Demographic information and details of presenting pathology are shown in ). Results of linear regression analysis were r=0.92 (p<0.001), β value=0.31 (SE=0.05) for patient one ( figure 3A) , and r=0.88 (p<0.01), β value=0.38 (SE=0.09) for patient two ( figure 3B ).
Discussion
To . This proportion is known as the relative recovery and is a consequence of the transit time of the perfusate along the semi-permeable microdialysis membrane being insufficient to allow complete equilibration between ECF and perfusate. Relative recovery of phenytoin has been investigated by several authors using a variety of catheter types, membrane lengths and perfusion rates 10, 15, 16 . However, it has not previously been reported for the commonly used catheter type and perfusion rate we describe in this study. We were not able to reproduce the results of one study showing a phenytoin relative recovery of 50% at a high flow rate of 1.65 μl/min There is also likely to be some variation in relative recovery across a patient group and this may therefore contribute to the range of values of microdialysate:plasma free phenytoin ratio. 
